Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study
Maria Fagerbakke Strømme, Mina Thue Augustsson, Christoffer Bartz-Johannessen, Andrea Stautland, Arnstein Mykletun, Rune Andreas Kroken, Lars Mehlum, Eirik Kjelby, Erik Johnsen · 2024
Read Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study by Maria Fagerbakke Strømme, Mina Thue Augustsson, Christoffer Bartz-Johannessen, Andrea Stautland, Arnstein Mykletun, Rune Andreas Kroken, Lars Mehlum, Eirik Kjelby, Erik Johnsen (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11780172.txt.
Introduction
Maria Fagerbakke Strømme and co-authors present a 2024 cohort study of medication use and suicidality in schizophrenia. About five percent of patients die by suicide, and skipping antipsychotic medicine is a known risk. How the three common drug classes interact over time was less clear.
The team followed 696 patients admitted to one acute psychiatric unit across ten years. Thirty-two suicide events occurred, nine completed and twenty-three attempted. In adjusted time-dependent models, taking antipsychotics came with about seventy percent lower risk of an attempt or death than not taking them. Antidepressant and sedative use were weighed in the same framework. The authors stress that adherence support is suicide prevention, and that drug classes should be judged together, not in isolation.
Catalog record
| CREATOR | Maria Fagerbakke Strømme, Mina Thue Augustsson, Christoffer Bartz-Johannessen, Andrea Stautland, Arnstein Mykletun, Rune Andreas Kroken, Lars Mehlum, Eirik Kjelby, Erik Johnsen |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Suicidality and use of psychotropic medications in patients with schizophrenia: a prospective cohort study Authors: Maria Fagerbakke Strømme, Mina Thue Augustsson, Christoffer Bartz-Johannessen, Andrea Stautland, Arnstein Mykletun, Rune Andreas Kroken, Lars Mehlum, Eirik Kjelby, Erik Johnsen Published: 2024 ABSTRACT AbstractBackgroundThe lifetime prevalence of suicide is around 5% in patients with schizophrenia. Non-adherence to antipsychotic medication is an important risk factor, but prospective studies investigating joint effects of antipsychotic drugs, antidepressants, and benzodiazepines on suicidality are scarce. We aimed to investigate how use and non-use of psychotropic medications are associated with suicidality in schizophrenia.MethodsAn open cohort study followed all patients consecutively admitted to a psychiatric acute unit during a 10-year period with a diagnosis of schizophrenia (n = 696). Cox multiple regression analyses were conducted with use of antipsychotics, antidepressants, and benzodiazepines as time-dependent variables. Adjustments were made for age, gender, depressive mood, agitated behavior, and use of alcohol and illicit substances.ResultsA total of 32 (4.6%) suicide events were registered during follow-up. Of these, 9 (28%) were completed suicides and 23 (72%) were attempted suicides. A total of 59 (8.5%) patients were readmitted with suicidal plans during the follow-up. Compared to non-use, use of antipsychotics was associated with 70% lower risk of attempted or completed suicide (adjusted hazard ratio [AHR] = 0.30, p < 0.01, CI 0.14–0.65) and 69% reduced risk of readmission with suicidal plans (AHR = 0.31, p < 0.01, CI 0.18–0.55). Use of prescribed benzodiazepines was associated with 126% increased risk of readmission with suicidal plans (AHR = 2.26, p = 0.01, CI 1.24–4.13).ConclusionsAdherence to antipsychotic medication is strongly associated with reduced suicidal risk in schizophrenia. The use of prescribed benzodiazepines was identified as a significant risk factor for being readmitted with suicidal plans.Keywords: antidepressants, antipsychotics, benzodiazepines, schizophrenia, suicide Introduction Suicide is a significant contributor to decreased life expectancy in patients with schizophrenia (Ko et al., 2018). Lifetime prevalence estimates are 50% for suicide attempt and 5% for completed suicide (Palmer, Pankratz, & Bostwick, 2005; Taipale, Lähteenvuo, Tanskanen, Mittendorfer-Rutz, & Tiihonen, 2021). Suicidal behavior in patients with schizophrenia is often directly linked to the symptoms of the disorder and typically occurs in the first decade after onset (Sher & Kahn, 2019). Certain symptoms of schizophrenia, such as delusions and hallucinations, as well as social isolation and illness awareness that leads to hopelessness, are associated with an increased risk of suicide (Hettige, Bani-Fatemi, Sakinofsky, & De Luca, 2018; Kjelby et al., 2015; Pjescic et al., 2014). Comorbid depression, a history of suicide attempts, and alcohol or substance abuse also represent major risk factors for both suicidal ideation and behavior (Cassidy, Yang, Kapczinski, & Passos, 2018; Hawton, Sutton, Haw, Sinclair, & Deeks, 2005; Hor & Taylor, 2010; Popovic et al., 2014; Sher & Kahn, 2019). Antipsychotic medication plays a pivotal role in the treatment of schizophrenia, effectively reducing hallucinations and delusions in the majority of patients (Dixon, Lehman, & Levine, 1995; Zhu et al., 2017). Consequently, antipsychotics may contribute to a reduction in suicidality associated with these symptoms. A study conducted by Taipale et al. (2021) found that all antipsychotic medications, and in particular clozapine, effectively reduced the suicide risk. Correspondingly, several studies show that lack of adherence to antipsychotic medication may increase the suicide risk (Forsman, Taipale, Masterman, Tiihonen, & Tanskanen, 2019; Haukka, Tiihonen, Harkanen, & Lonnqvist, 2008; Pompili et al., 2009). A large registry-based study by Tiihonen et al. (2006b) reported that compared to use of antipsychotic medications, non-use is associated with a 37-fold increase in suicide risk in patients with schizophrenia. On the flip side, antipsychotic drugs may elicit a spectrum of adverse effects, including akathisia (psychomotor restlessness). Previous studies have suggested that akathisia may contribute to an elevated risk of suicidality in individuals with schizophrenia (Bjarke et al., 2022; Seemuller et al., 2012). However, it is important to note that despite some findings indicating increased suicide risk with antipsychotics, current literature strongly supports the notion that antipsychotic medications offer a robust protective effect for suicidality in patients with schizophrenia. Adjunctive psychotropic drugs, in particular antidepressants and benzodiazepines, are commonly prescribed alongside antipsychotic drugs in the treatment of schizophrenia. A review conducted by Zink, Englisch, and Meyer-Lindenberg (2010) reported that approximately 70% of individuals with schizophrenia received a combination of antipsychotics and other psychotropic drugs. Despite limited evidence for added beneficial effects (Gregory, Mallikarjun, & Upthegrove, 2017), antidepressants are frequently co-prescribed for depressive or persistent negative symptoms, such as a lack of interest and initiative (Baandrup, 2020; Ballon & Stroup, 2013). Given that depression is a well-known risk factor for suicide, antidepressant treatment could offer a protective effect. However, demonstrating this connection has proven to be challenging, as there is conflicting evidence regarding the association between antidepressants and suicide risk (Dragioti et al., 2019; Haukka et al., 2008). Benzodiazepines are commonly used in the acute treatment of psychosis, primarily to induce sleep or to alleviate anxiety and agitated behavior (Ballon & Stroup, 2013). As both insomnia and anxiety are common in patients with schizophrenia and generally linked to an elevated risk of suicide (Garay, Samalin, Hameg, & Llorca, 2015; Miller, McEvoy, & McCall, 2023), it may appear intuitive that short-term benzodiazepine use has a beneficial effect on suicide risk in patients with schizophrenia. However, the use of benzodiazepines comes with a range of adverse effects, including addiction and withdrawal symptoms, and several studies have indicated that benzodiazepine use is associated with an increased risk of suicide (Dodds, 2017; Tiihonen, Mittendorfer-Rutz, Torniainen, Alexanderson, & Tanskanen, 2016; Tiihonen, Suokas, Suvisaari, Haukka, & Korhonen, 2012). A review by Dodds (2017) concluded that benzodiazepines appear to cause increased risk of attempted and completed suicide, potentially due to factors such as withdrawal symptoms, overdoses or heightened levels of aggression and impulsivity. Taken together, suicidality represents a major concern in patients with schizophrenia. While previous studies have emphasized non-adherence to antipsychotic medication as a risk factor for suicide in patients with schizophrenia (Forsman et al., 2019; Haukka et al., 2008), this study contributes with new knowledge regarding the impact of adjunctive medications on suicidality in this population. Non-adherence and concomitant psychotropic treatment are prevalent in clinical practice, but prospective studies investigating the effect of antipsychotic drugs, antidepressants, and benzodiazepines on suicidality in a real-life clinical setting are scarce. With a large cohort, a follow-up period of up to 10 years, and the possibility to take account for potentially confounding factors such as alcohol or substance abuse, depression, and aggression, the present study can provide a robust analysis of the association between suicidality and use of different psychotropic drugs. Accordingly, the aim of this study is to investigate how the use and non-use of psychotropic medications are associated with the risk of readmission with suicidal plans and attempted or completed suicide in patients with schizophrenia. Material and methods A major part of the material and methods has been outlined in three prior publications by Stromme et al. (Stromme et al. 2021, 2022b; Strømme, Bartz-Johannesen, Kroken, Mehlum, & Johnsen, 2022a), all stemming from the same study cohort, but are specified as follows: Sample The study was carried out at the Division of Psychiatry, Haukeland University Hospital, Bergen, Norway. The hospital serves approximately 95% of individuals requiring acute psychiatric hospitalization in an area with a catchment